Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02746705 · ClinicalTrials.gov registry record · NA

Pilot Study of Transcranial Direct Current Stimulation (tDCS)

A NA study of Multiple Sclerosis, sponsored by NYU Langone Health.

Completed
Registry status
NA
Development phase
31
Enrollment target
1
Study location

NCT02746705 is a NA study of Multiple Sclerosis that has completed, run by NYU Langone Health. The registered enrollment target is 31 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02746705, a NA study of Multiple Sclerosis, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

This study will test the tolerability and preliminary efficacy of transcranial direct current stimulation (tDCS) combined with a cognitive training program, remotely-delivered using a telemedicine protocol in 60 adults with multiple sclerosis (MS). The study will evaluate the efficacy of tDCS to evaluate two of the most debilitating symptoms of MS: cognitive impairment and fatigue.

Conditions Studied

Interventions

  • DEVICE Transcranial Direct Current Stimulation (tDCS)
  • DEVICE Sham Transcranial Direct Current Stimulation
  • BEHAVIORAL Cognitive Training Program

Study Locations (1)

New York

  • New York University Langone Medical Center - New York

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2016-04
Est. Completion 2018-09-30
Phase NA

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT02746705

The ClinicalTrials.gov registry entry for NCT02746705 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (95% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Transcranial Direct Current Stimulation (tDCS) is the first listed.

NCT02746705 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02746705 about?

NCT02746705 is a clinical study titled "Pilot Study of Transcranial Direct Current Stimulation (tDCS)". This study will test the tolerability and preliminary efficacy of transcranial direct current stimulation (tDCS) combined with a cognitive training program, remotely-delivered using a telemedicine protocol in 60 adults with multiple sclerosis (MS). The study will evaluate the efficacy of tDCS to eva...

What is the current status of trial NCT02746705?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2016-04. Estimated completion is 2018-09-30.

What conditions does trial NCT02746705 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT02746705?

The interventions under investigation include: Transcranial Direct Current Stimulation (tDCS) (DEVICE), Sham Transcranial Direct Current Stimulation (DEVICE), Cognitive Training Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT02746705?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02746705 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.